Life Sciences Nova Scotia
  • About
    • Who We Are
    • What we do
    • Why work in Nova Scotia?
    • Contact us
  • Members
    • Member Directory
    • Member Benefits
    • Become a member
  • Resources
    • Member Programs
    • News and success stories
    • Member Job Board
  • Events
    • Events
    • BioPort Atlantic
    • Atlantic Precision Medicine Conference
  • Podcast
Select Page

Xultophy® approved in Canada for the treatment of adults with type 2 diabetes

by administrator | Apr 18, 2018 | News, Novo Nordisk

See original story here Once-daily Xultophy® has been shown to help patients achieve blood glucose targets Novo Nordisk announced today that Health Canada has approved Xultophy®as an adjunct to lifestyle modifications, for the once-daily treatment of adults with type...

Recent Posts

  • Sona Nanotech’s Cancer Therapy Shows Potential in New Study
  • Twelve Start-ups Selected for First Cohort of 2026-2027 Accelerate
  • Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
  • ABK Biomedical Closed $35M Financing Round in 2025
  • Elle, MD Named CIX Startup Award Winner
No comments to show.
[buddybot_chat id=1]

Life Sciences Nova Scotia is the organization to help fuel your success.

Join today
  • WHO WE ARE
  • EVENTS
  • MEMBER PROGRAMS
  • CONTACT US
  • MEMBERS
  • NEWS & SUCCESS STORIES
  • Follow
  • Follow